Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma

Monitoring of exhaled nitric oxide (FENO) to tailor the lowest effective dose of oral corticosteroids in severe asthma - MONOSA-study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON30375

Enrollment

100

Registered

2007-01-23

Start date

2007-01-01

Completion date

Unknown

Last updated

2024-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe asthma steroid-dependent asthma

Interventions

see Study design

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18-65 years - pulmonologist's diagnosis of severe asthma - daily or alternate day oral corticosteroid therapy for at least 1 month before entering into the study - maintenance high dose inhaled corticosteroids (at least 1600 mcg/day beclomethasone equivalent) and long- and short acting bronchodilators for more than one year

Exclusion criteria

Exclusion criteria: - The patient is not able to perform adequate measurements of FENO at home - The patient has no mobile phone or internet access

Design outcomes

Primary

Measure	Time frame
Cumulative dose of oral corticosteroids, symptoms (ACQ), quality of life (AQLQ), patient's health state (VAS).	—

Secondary

Measure	Time frame
EQ-5D, SF-12, lung function, exacerbations, emergency visits, hospitalisations, steroid side effects	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)